Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
The thymidylate synthase (TS) content of tumor tissue was assayed and the levels of 5-fluorouracil (5-Fu) in serum and tumor tissue were determined in 21 patients with cervical cancer who were treated with UFT, a fluorinated pyrimidine. Subrenal capsule assay, a predictive tumor sensitivity test, was conducted concurrently on cervical tumor samples. TS inhibition and serum and tissue 5-Fu levels widely varied between both samples. Investigation of the relationship between the tumor growth inhibition rate determined by subrenal capsule assay and the above parameters (TS inhibition, serum and tissue 5-Fu levels) showed that TS inhibition and tumor growth inhibition were well correlated (r = 0.73). This suggests that a TS inhibition assay in tumor tissue can be a useful predictive test for tumor sensitivity of fluorinated pyrimidines.
Suzuki
M
M
Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan.
Sekiguchi
I
I
Tamada
T
T
D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D005260:Female; D006801:Humans; D051379:Mice; D008875:Middle Aged; D013370:Subrenal Capsule Assay; D005641:Tegafur / Q000008:administration & dosage; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D014498:Uracil / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000201:enzymology
D005641:Tegafur; D014498:Uracil; D013940:Thymidylate Synthase